[
  {
    "ts": null,
    "headline": "Hawaii in $700 million settlement with Bristol-Myers, Sanofi over Plavix warning label",
    "summary": "Hawaii said on Friday it entered a$700 million settlement with pharmaceutical firm Bristol-MyersSquibb and units of French pharmaceutical company Sanofiin a case about warning labels related to...",
    "url": "https://finnhub.io/api/news?id=c3d7f3fbecbf92d2f49c1b5a83f237836cf037dc7d86f05fe7852297c8177fef",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746827047,
      "headline": "Hawaii in $700 million settlement with Bristol-Myers, Sanofi over Plavix warning label",
      "id": 134361160,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "Hawaii said on Friday it entered a$700 million settlement with pharmaceutical firm Bristol-MyersSquibb and units of French pharmaceutical company Sanofiin a case about warning labels related to...",
      "url": "https://finnhub.io/api/news?id=c3d7f3fbecbf92d2f49c1b5a83f237836cf037dc7d86f05fe7852297c8177fef"
    }
  },
  {
    "ts": null,
    "headline": "3 Healthcare Stocks in Hot Water",
    "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 13.3%. This drawdown was worse than the S&P 500’s 5.8% fall.",
    "url": "https://finnhub.io/api/news?id=85ddfb537b8460d1d584298c0e9c1285a61cf4433bd55849a940a825d844d9b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746765540,
      "headline": "3 Healthcare Stocks in Hot Water",
      "id": 134335980,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 13.3%. This drawdown was worse than the S&P 500’s 5.8% fall.",
      "url": "https://finnhub.io/api/news?id=85ddfb537b8460d1d584298c0e9c1285a61cf4433bd55849a940a825d844d9b7"
    }
  }
]